Skip to article frontmatterSkip to article content
Site not loading correctly?

This may be due to an incorrect BASE_URL configuration. See the MyST Documentation for reference.

5. Data Sources and Input Files

Independent / quantitative investing

5.1 IBD Big Cap 20 / Big Cap 50 (IBD 50 screen)

5.2 IBD RS Master

5.3 E*TRADE portfolio export

5.4 yfinance

5.5 ^TNX (risk-free rate)

5.4 MarketSurge (Optional Premium Upgrade)

What it is: IBD’s professional screening and charting platform. Formerly known as MarketSmith.

Cost: 49.95for6−weektrial∣49.95 for 6-week trial | 1,499/year annual

Key features not in current system:

Current workaround (V1):

V2 plan — three-tier approach:

Tier 1 (Now — free): Systematic daily Big Picture reading Add buy point mentions from Big Picture to weekly journal Cross-reference against conviction list manually

Tier 2 (Week 12 — $49.95 trial): Test MarketSurge Evaluate Breaking Out Today vs system conviction list overlap Measure whether Near Pivot list improves entry timing Decision: subscribe annually if adds measurable value

Tier 3 (V2 code — free): Build proximity detection Add 52-week high proximity score to ingest_ibd_lists.py Flag stocks within 5% of 52-week high as NEAR_PIVOT This approximates Near Pivot list without MarketSurge cost

ROI threshold for annual subscription: 1,499/year=1,499/year = 125/month Must prevent 2-3 bad entries per year OR Must identify 1-2 breakouts missed without it Evaluate after 6-week trial at Week 12

Note on data independence: MarketSurge uses IBD proprietary data — same IP constraints as current IBD Digital subscription. If moving toward data independence (Path 2), MarketSurge is not on that path. Own RS calculation (Enhancement 4) + yfinance 52-week high proximity is the data-independent alternative.